Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 7/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.35 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709415 | 0.96 | BDKRB1 (0.39) | BDKRB1HCRTR1HCRTR2FKBP1AFKBP4 | |
| SCHEMBL702287 | 0.91 | HCRTR1 (0.36) | BDKRB1HCRTR1HCRTR2FKBP1AFKBP4 | |
| SCHEMBL701428 | 0.90 | HCRTR1 (0.35) | BDKRB1HCRTR1HCRTR2FKBP1AFKBP4 | |
| SCHEMBL5128577 | 0.88 | MEN1 (0.43) | BDKRB1HCRTR1HCRTR2ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL5125263 | 0.87 | MEN1 (0.43) | BDKRB1HCRTR1HCRTR2ALDH1A1POLB | |
| SCHEMBL3441828 | 0.82 | BDKRB1 (0.36) | BDKRB1HCRTR1HCRTR2FKBP1AFKBP4 | |
| SCHEMBL3441613 | 0.82 | BDKRB1 (0.36) | BDKRB1HCRTR1HCRTR2FKBP1AFKBP4 | |
| SCHEMBL3406175 | 0.82 | BDKRB1 (0.41) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3442255 | 0.81 | BDKRB1 (0.35) | BDKRB1HCRTR1HCRTR2FKBP1AFKBP4 | |
| SCHEMBL3441953 | 0.81 | BDKRB1 (0.35) | BDKRB1HCRTR1HCRTR2FKBP1AFKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | BDKRB1 11/4885HCRTR1 369/4885HCRTR2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.